Skip to content
GLP-1 Scorecard
Menu

Head-to-head · WeighScore

Breeze Meds vs HumeCare+

By GLP-1 ScorecardUpdated

Breeze Meds
Site position #90

Higher grade

HumeCare+
Site position #328

Lower grade

Score comparison

Breeze Meds has the higher recorded score — 72.4/100 to 58.6/100.

Breeze Meds grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. Charges nothing until a provider approves you — but keeps its pricing inside the intake.

We may earn a commission through these links, at no extra cost to you. Commercial relationships affect placement, but never the WeighScore or our editorial findings. See our disclosure.

Factor by factor

These are recorded editorial marks, not a measure of clinical outcomes. Current prices and terms may differ from those used in the marks. See the methodology.

Cost valueBreeze Meds +18
72
54
Dose & formulationBreeze Meds +14
66
52
Clinical oversightBreeze Meds +5
76
71
Labs & monitoringBreeze Meds +7
60
53
FulfillmentBreeze Meds +20
84
64
Contract termsBreeze Meds +25
86
61
Breeze Meds · top barHumeCare+ · bottom bar

The numbers

Swipe or scroll to compare both providers.

MetricBreeze MedsHumeCare+
WeighScore72.4/10058.6/100
GradeCC
Site position#90#328
SemaglutideFrom $199/moGLP-1 page advertises $199 billed monthly and a first four-week supply; homepage labels a three-month plan from $199/month. Confirm the selected total and formulation additions.
TirzepatideFrom $299/mo first month, $399/mo thereafterNamed on the public GLP-1 menu, but no separate current public prescription price confirmed; obtain the selected medication and renewal quote.
CoverageAll 50 statesHomepage/footer exclude Louisiana and Mississippi; GLP-1 FAQ also excludes Alabama. Confirm current treatment-specific eligibility, especially Alabama.
Brand-name accessNot confirmedNot confirmed
Oral / sublingualNot confirmedNot confirmed
Breeze Meds

Site position #90 · C

Strengths

  • Nothing charged until a provider approves you, and the consult is free if you go ahead
  • One inclusive price covering consult, medication, supplies, shipping and support
  • LegitScript certified, all 50 states, cancel or change plan at any time
  • NAD+ injections offered alongside the GLP-1 line

What to consider

  • The public site names no molecule behind its "from $199" — tirzepatide pricing appears only inside the intake
  • Every quoted figure is for the LOWEST dose; the funnel says higher doses may cost more
  • An $80 consultation fee applies if you are approved and then decline
  • Injection only, compounded only, with no published lab program
HumeCare+

Site position #328 · C

Strengths

  • Advertises a Hume Pod and app within the homepage package; other selected plans may differ
  • Current terms describe a single subscription including consultation and prescribed fulfilled medication, with added charges requiring disclosure and consent
  • Publicly identifies MDI Medical Group PC as the clinical network and provides a clinician directory; assignment and current individual licenses still need confirmation
  • Terms allow cancellation before renewal through the account Subscription section or support email

What to consider

  • Homepage three-month pricing and the GLP-1 page’s monthly billing description do not establish one selected initial charge or renewal calendar
  • Ninety-day, 180-day and six-month results-refund advertisements do not have matching claim rules in the current terms; customer-canceled prepaid periods are not prorated
  • Muscle-preservation, side-effect and outcome advantages are merchant claims, not established benefits of the prescribed compound or tracking device
  • No exact prescribing dose, vial quantity, usable supply or patient-lab price is confirmed by the public package
  • The dispensing pharmacy and physical compounder are not named in the reviewed terms or shipping policy
  • Alabama availability differs between the GLP-1 FAQ and site footer; general eligibility does not guarantee every preparation
  • Next-day advertising differs from published clinical-review, pharmacy-processing and carrier estimates; a free included device does not create a separate device cash refund

Featured provider

HumeCare+

HumeCare+ scores 58.6/100 (C). Pairs advertised GLP-1 care with connected body-composition tracking, while public pages differ on payment periods, delivery and refund promises.

Commercial relationships affect this placement. The score comparison above is separate.

Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.

← Back to the scorecard